Synaptic changes induced by melanocortin signalling

Nature Reviews Neuroscience

Volumn 15, Issue 2, 2014, Pages 98-110

  Caruso, Vanni ^a   Lagerström, Malin C ^a   Olszewski, Pawel K ^a,b   Fredriksson, Robert ^a   Schiöth, Helgi B ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF WAIKATO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOCORTIN; MELANOCORTIN 4 RECEPTOR;

CHRONIC PAIN; DEPRESSION; DRUG ABUSE; HOMEOSTASIS; HUMAN; LEARNING; MEMORY DISORDER; MOOD DISORDER; NERVE CELL PLASTICITY; NOCICEPTION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; REWARD; SIGNAL TRANSDUCTION;

ANIMALS; CELL ADHESION MOLECULES, NEURONAL; DEPRESSIVE DISORDER; ENERGY METABOLISM; HUMANS; MELANOCORTINS; MEMORY DISORDERS; PAIN; RECEPTOR, MELANOCORTIN, TYPE 4; SIGNAL TRANSDUCTION; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84892748471     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn3657     Document Type: Review

References (223)

1. Caruso, C. , Carniglia, L. , Durand, D. , Scimonelli, T. N. & Lasaga, M. in Neurodegeneration (ed. Martins, L. M. ) 93-120 (InTech, 2012). This is a comprehensive review focusing on the anti-inflammatory and neuroprotective role of melanocortins in the CNS.
2. Tao, Y. X. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr. Rev. 31, 506-543 (2010). This review summarizes studies on MC4R, from its cloning to its physiological roles in energy homeostasis, lipid homeostasis and inflammation.
3. Cone, R. D. Anatomy and regulation of the central melanocortin system. Nature Neurosci. 8, 571-578 (2005).
4. Bertolini, A. , Tacchi, R. & Vergoni, A. V. Brain effects of melanocortins. Pharmacol. Res. 59, 13-47 (2009).
5. Gonzalez, P. V. , Schioth, H. B. , Lasaga, M. & Scimonelli, T. N. Memory impairment induced by IL-1? is reversed by ?-MSH through central melanocortin-4 receptors. Brain Behav. Immun. 23, 817-822 (2009).
6. Bertolini, A. , Poggioli, R. & Ferrari, W. ACTH-induced hyperalgesia in rats. Experientia 35, 1216-1217 (1979).
7. Winter, C. A. & Flataker, L. The effect of cortisone, desoxycorticosterone, and adrenocorticotrophic hormone upon the responses of animals to analgesic drugs. J. Pharmacol. Exp. Ther. 103, 93-105 (1951).
8. Nakanishi, S. et al. Nucleotide sequence of cloned cDNA for bovine corticotropin-?-lipotropin precursor. Nature 278, 423-427 (1979).
9. Wardlaw, S. L. Hypothalamic proopiomelanocortin processing and the regulation of energy balance. Eur. J. Pharmacol. 660, 213-219 (2011).
10. Argiolas, A. & Melis, M. R. Neuropeptides and central control of sexual behaviour from the past to the present: a review. Prog. Neurobiol. 108, 80-107 (2013).
11. Vergoni, A. V. , Schioth, H. B. & Bertolini, A. Melanocortins and feeding behavior. Biomed. Pharmacother. 54, 129-134 (2000).
12. Chhajlani, V. & Wikberg, J. E. Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA. FEBS Lett. 309, 417-420 (1992).
13. Mountjoy, K. G. , Robbins, L. S. , Mortrud, M. T. & Cone, R. D. The cloning of a family of genes that encode the melanocortin receptors. Science 257, 1248-1251 (1992).
14. Chhajlani, V. , Muceniece, R. & Wikberg, J. E. Molecular cloning of a novel human melanocortin receptor. Biochem. Biophys. Res. Commun. 195, 866-873 (1993).
15. Roselli-Rehfuss, L. et al. Identification of a receptor for ? melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc. Natl Acad. Sci. USA 90, 8856-8860 (1993).
16. Gantz, I. et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J. Biol. Chem. 268, 15174-15179 (1993).
17. Labbe, O. , Desarnaud, F. , Eggerickx, D. , Vassart, G. & Parmentier, M. Molecular cloning of a mouse melanocortin 5 receptor gene widely expressed in peripheral tissues. Biochemistry 33, 4543-4549 (1994).
18. Schioth, H. B. The physiological role of melanocortin receptors. Vitam. Horm. 63, 195-232 (2001). This is a comprehensive review focusing on the biochemistry and physiological role of melanocortin receptors.
19. Yang, Y. Structure, function and regulation of the melanocortin receptors. Eur. J. Pharmacol. 660, 125-130 (2011).
20. Gantz, I. & Fong, T. M. The melanocortin system. Am. J. Physiol. Endocrinol. Metab. 284, E468-E474 (2003).
21. Cone, R. D. et al. The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog. Horm. Res. 51, 287-317 (1996).
22. Wikberg, J. E. & Mutulis, F. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. Nature Rev. Drug Discov. 7, 307-323 (2008).
23. Kask, A. , Rägo, L. , Wikberg, J. E. S. & Schiöth, H. B. Evidence for involvement of the melanocortin MC4R in the effects of leptin on food intake and body weight. Eur. J. Pharmacol. 360, 15-19 (1998).
24. Morton, G. J. , Cummings, D. E. , Baskin, D. G. , Barsh, G. S. & Schwartz, M. W. Central nervous system control of food intake and body weight. Nature 443, 289-295 (2006).
25. Huszar, D. et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88, 13-141 (1997).
26. Yaswen, L. , Diehl, N. , Brennan, M. B. & Hochgeschwender, U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nature Med. 5, 1066-1070 (1999).
27. Ollmann, M. M. et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278, 135-138 (1997).
28. Giuliani, D. et al. Melanocortins protect against progression of Alzheimer's disease in triple-transgenic mice by targeting multiple pathophysiological pathways. Neurobiol. Aging 35, 537-547 (2014).
29. Giuliani, D. et al. Both early and delayed treatment with MC4R-stimulating melanocortins produces neuroprotection in cerebral ischemia. Endocrinology 147, 1126-1135 (2006).
30. Hache, G. et al. Antinociceptive effects of fluoxetine in a mouse model of anxiety/depression. Neuroreport 23, 525-529 (2012).
31. Bar, K. J. et al. Pain perception in major depression depends on pain modality. Pain 117, 97-103 (2005).
32. Apkarian, A. V. A brain signature for acute pain. Trends Cogn. Sci. 17, 309-310 (2013).
33. Mansour, A. R. , Farmer, M. A. , Baliki, M. N. & Apkarian, A. V. Chronic pain: the role of learning and brain plasticity. Restor. Neurol. Neurosci. http:// dx. doi. org/10. 3233/RNN-139003 (2013).
34. Zimmerman, M. E. et al. Hippocampal correlates of pain in healthy elderly adults: a pilot study. Neurology 73, 1567-1570 (2009).
35. Mutso, A. A. et al. Abnormalities in hippocampal functioning with persistent pain. J. Neurosci. 32, 5747-5756 (2012).
36. Lim, B. K. , Huang, K. W. , Grueter, B. A. , Rothwell, P. E. & Malenka, R. C. Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens. Nature 487, 183-189 (2012). This study demonstrates that activation of MC4R in the NAc leads to a depression of excitatory synaptic transmission accompanied by changes in the stoichiometry of AMPAR in the mouse.
37. Shen, Y. , Fu, W. Y. , Cheng, E. Y. , Fu, A. K. & Ip, N. Y. Melanocortin-4 receptor regulates hippocampal synaptic plasticity through a protein kinase A-dependent mechanism. J. Neurosci. 33, 464-472 (2013). This study demonstrates that in vivo administration of MC4R agonists increases LTP in the hippocampal CA1 region of mice, elucidating its functional role in synaptic plasticity.
38. Grueter, B. A. , Rothwell, P. E. & Malenka, R. C. Integrating synaptic plasticity and striatal circuit function in addiction. Curr. Opin. Neurobiol. 22, 545-551 (2012).
39. Kreitzer, A. C. & Malenka, R. C. Striatal plasticity and basal ganglia circuit function. Neuron 60, 543-554 (2008).
40. Russo, S. J. et al. The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbens. Trends Neurosci. 33, 267-276 (2010).
41. Alvaro, J. D. et al. Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction. Mol. Pharmacol. 50, 583-591 (1996).
42. Alvaro, J. D. , Taylor, J. R. & Duman, R. S. Molecular and behavioral interactions between central melanocortins and cocaine. J. Pharmacol. Exp. Ther. 304, 391-399 (2003). This study supports the role for MC4R in the biochemical and behavioural effects of drug of abuse.
43. Barrientos, R. M. et al. BDNF mRNA expression in rat hippocampus following contextual learning is blocked by intrahippocampal IL-1? administration. J. Neuroimmunol. 155, 119-126 (2004).
44. Cui, H. & Lutter, M. The expression of MC4Rs in D1R neurons regulates food intake and locomotor sensitization to cocaine. Genes Brain Behav. 12, 658-665 (2013). This study elucidates the physiological role of MC4R-mediated signalling within D1R-expressing neurons and the behavioural response to cocaine.
45. Ercil, N. E. , Galici, R. & Kesterson, R. A. HS014, a selective melanocortin-4 (MC4) receptor antagonist, modulates the behavioral effects of morphine in mice. Psychopharmacology (Berl. ) 180, 279-285 (2005).
46. Liu, J. , Garza, J. C. , Li, W. & Lu, X. Y. Melanocortin-4 receptor in the medial amygdala regulates emotional stress-induced anxiety-like behaviour, anorexia and corticosterone secretion. Int. J. Neuropsychopharmacol. 16, 105-120 (2013).
47. Hsu, R. et al. Blockade of melanocortin transmission inhibits cocaine reward. Eur. J. Neurosci. 21, 2233-2242 (2005).
48. Niikura, K. , Zhou, Y. , Ho, A. & Kreek, M. J. Proopiomelanocortin (POMC) expression and conditioned place aversion during protracted withdrawal from chronic intermittent escalating-dose heroin in POMC-EGFP promoter transgenic mice. Neuroscience 236, 220-232 (2013).
49. Cabeza de Vaca, S. , Kim, G. Y. & Carr, K. D. The melanocortin receptor agonist MTII augments the rewarding effect of amphetamine in ad-libitum-fed and food-restricted rats. Psychopharmacology (Berl. ) 161, 77-85 (2002).
50. Chaki, S. & Okuyama, S. Involvement of melanocortin-4 receptor in anxiety and depression. Peptides 26, 1952-1964 (2005). This study investigates the relationship between MC4R and stress related disorders, suggesting that MC4R might be related to stress-induced changes in behaviour, and blockade of MC4R may prevent stress-induced disorders such as anxiety.
51. McLay, R. N. , Pan, W. & Kastin, A. J. Effects of peptides on animal and human behavior: a review of studies published in the first twenty years of the journal Peptides. Peptides 22, 2181-2255 (2001).
52. Cheung, Z. H. & Ip, N. Y. From understanding synaptic plasticity to the development of cognitive enhancers. Int. J. Neuropsychopharmacol. 14, 1247-1256 (2011).
53. Bliss, T. V. & Collingridge, G. L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361, 31-39 (1993).
54. Kandel, E. R. The molecular biology of memory storage: a dialog between genes and synapses. Biosci. Rep. 21, 565-611 (2001).
55. Cui, H. et al. Melanocortin 4 receptor signaling in dopamine 1 receptor neurons is required for procedural memory learning. Physiol. Behav. 106, 201-210 (2012).
56. Oosterom, J. et al. Common requirements for melanocortin-4 receptor selectivity of structurally unrelated melanocortin agonist and endogenous antagonist, Agouti protein. J. Biol. Chem. 276, 931-936 (2001).
57. Abel, T. & Nguyen, P. V. Regulation of hippocampus-dependent memory by cyclic AMP-dependent protein kinase. Prog. Brain Res. 169, 97-115 (2008).
58. Kopec, C. D. , Real, E. , Kessels, H. W. & Malinow, R. GluR1 links structural and functional plasticity at excitatory synapses. J. Neurosci. 27, 13706-13718 (2007).
59. Man, H. Y. , Sekine-Aizawa, Y. & Huganir, R. L. Regulation of ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor trafficking through PKA phosphorylation of the Glu receptor 1 subunit. Proc. Natl Acad. Sci. USA 104, 3579-3584 (2007).
60. Caruso, C. et al. Melanocortin 4 receptor activation induces brain-derived neurotrophic factor expression in rat astrocytes through cyclic AMP-protein kinase A pathway. Mol. Cell. Endocrinol. 348, 47-54 (2012). This is the first study to show that MC4R activation in astrocytes induces BDNF expression through the cAMP-PKA-CREB pathway without involving nuclear factor-kB.
61. Kelley, A. E. Ventral striatal control of appetitive motivation: role in ingestive behavior and reward-related learning. Neurosci. Biobehav. Rev. 27, 765-776 (2004).
62. Nishi, A. , Kuroiwa, M. & Shuto, T. Mechanisms for the modulation of dopamine D1 receptor signaling in striatal neurons. Front. Neuroanat. 5, 43 (2011).
63. Korte, M. , Kang, H. , Bonhoeffer, T. & Schuman, E. A role for BDNF in the late-phase of hippocampal long-term potentiation. Neuropharmacology 37, 553-559 (1998).
64. Kandel, E. R. The molecular biology of memory storage: a dialogue between genes and synapses. Science 294, 1030-1038 (2001).
65. Pang, P. T. et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 306, 487-491 (2004).
66. Tyler, W. J. , Alonso, M. , Bramham, C. R. & Pozzo-Miller, L. D. From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. Learn. Mem. 9, 224-237 (2002).
67. Lee, J. L. , Everitt, B. J. & Thomas, K. L. Independent cellular processes for hippocampal memory consolidation and reconsolidation. Science 304, 839-843 (2004).
68. Bekinschtein, P. et al. Persistence of long-term memory storage requires a late protein synthesis-and BDNF-dependent phase in the hippocampus. Neuron 53, 261-277 (2007).
69. Goshen, I. et al. A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology 32, 1106-1115 (2007).
70. Schneider, H. et al. A neuromodulatory role of interleukin-1? in the hippocampus. Proc. Natl Acad. Sci. USA 95, 7778-7783 (1998).
71. Vereker, E. , O'Donnell, E. & Lynch, M. A. The inhibitory effect of interleukin-1? on long-term potentiation is coupled with increased activity of stress-activated protein kinases. J. Neurosci. 20, 6811-6819 (2000).
72. Yoon, S.-W. et al. ?-melanocyte-stimulating hormone inhibits lipopolysaccharide-induced tumor necrosis factor-? production in leukocytes by modulating protein kinase A, p38 kinase, and nuclear factor ?B signaling pathways. J. Biol. Chem. 278, 32914-32920 (2003).
73. Lai, A. Y. , Swayze, R. D. , El-Husseini, A. & Song, C. Interleukin-1 beta modulates AMPA receptor expression and phosphorylation in hippocampal neurons. J. Neuroimmunol. 175, 97-106 (2006).
74. Viviani, B. et al. Interleukin-1? enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J. Neurosci. 23, 8692-8700 (2003).
75. Lynch, G. , Larson, J. , Kelso, S. , Barrionuevo, G. & Schottler, F. Intracellular injections of EGTA block induction of hippocampal long-term potentiation. Nature 305, 719-721 (1983).
76. Dash, P. K. , Hochner, B. & Kandel, E. R. Injection of the cAMP-responsive element into the nucleus of Aplysia sensory neurons blocks long-term facilitation. Nature 345, 718-721 (1990).
77. Breit, A. et al. Alternative G protein coupling and biased agonism: new insights into melanocortin-4 receptor signalling. Mol. Cell. Endocrinol. 331, 232-240 (2011).
78. Caruso, C. M. , Carniglia, L. , Durand, D. , Scimonelli, T. N. & Lasaga, M. Astrocytes: new targets of melanocortin 4 receptor actions. J. Mol. Endocrinol. 51, R33-R50 (2013).
79. Spaccapelo, L. et al. Melanocortin MC4R agonists counteract late inflammatory and apoptotic responses and improve neuronal functionality after cerebral ischemia. Eur. J. Pharmacol. 670, 479-486 (2011). This study provides direct evidence that stimulation of MC4R affords neuroprotection and promotes functional recovery from stroke.
80. Giuliani, D. et al. Treatment of cerebral ischemia with melanocortins acting at MC4Rs induces marked neurogenesis and long-lasting functional recovery. Acta Neuropathol. 122, 443-453 (2011).
81. Giuliani, D. et al. Functional recovery after delayed treatment of ischemic stroke with melanocortins is associated with overexpression of the activity-dependent gene Zif268. Brain Behav. Immun. 23, 844-850 (2009).
82. Ferrari, W. Behavioural changes in animals after intracisternal injection with adrenocorticotrophic hormone and melanocyte-stimulating hormone. Nature 181, 925-926 (1958).
83. de Wied, D. , Witter, A. , Versteeg, D. H. & Mulder, A. H. Release of ACTH by substances of central nervous system origin. Endocrinology 85, 561-569 (1969).
84. Guarini, S. , Bazzani, C. & Bertolini, A. Role of neuronal and vascular Ca2+-channels in the ACTH-induced reversal of haemorrhagic shock. Br. J. Pharmacol. 109, 645-650 (1993).
85. Giuliani, D. et al. Melanocortins and the cholinergic anti-inflammatory pathway. Adv. Exp. Med. Biol. 2681, 2071-2087 (2010).
86. Cole, A. J. , Saffen, D. W. , Baraban, J. M. & Worley, P. F. Rapid increase of an immediate early gene messenger RNA in hippocampal neurons by synaptic NMDA receptor activation. Nature 340, 474-476 (1989).
87. Maniam, J. & Morris, M. J. The link between stress and feeding behaviour. Neuropharmacology 63, 97-110 (2012).
88. Mitra, A. et al. Expression levels of genes encoding melanin concentrating hormone (MCH) and MCH receptor change in taste aversion, but MCH injections do not alleviate aversive responses. Pharmacol. Biochem. Behav. 100, 581-586 (2012).
89. Kishi, T. et al. Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J. Comp. Neurol. 457, 213-235 (2003).
90. Cui, G. , Bernier, B. E. , Harnett, M. T. & Morikawa, H. Differential regulation of action potential-and metabotropic glutamate receptor-induced Ca2+ signals by inositol 1,4,5-trisphosphate in dopaminergic neurons. J. Neurosci. 27, 4776-4785 (2007).
91. Woolfrey, K. M. et al. Epac2 induces synapse remodeling and depression and its disease-associated forms alter spines. Nature Neurosci. 12, 1275-1284 (2009).
92. Oh, M. C. , Derkach, V. A. , Guire, E. S. & Soderling, T. R. Extrasynaptic membrane trafficking regulated by GluR1 serine 845 phosphorylation primes AMPA receptors for long-term potentiation. J. Biol. Chem. 281, 752-758 (2006).
93. Adan, R. A. et al. Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat. Eur. J. Pharmacol. 378, 249-258 (1999).
94. Mul, J. D. et al. Melanocortin receptor 4 deficiency affects body weight regulation, grooming behavior, and substrate preference in the rat. Obesity 20, 612-621 (2012).
95. Lu, X. Y. , Barsh, G. S. , Akil, H. & Watson, S. J. Interaction between ?-melanocyte-stimulating hormone and corticotropin-releasing hormone in the regulation of feeding and hypothalamo-pituitary-adrenal responses. J. Neurosci. 23, 7863-7872 (2003).
96. Sarkar, S. , Legradi, G. & Lechan, R. M. Intracerebroventricular administration of ?-melanocyte stimulating hormone increases phosphorylation of CREB in TRH-and CRH-producing neurons of the hypothalamic paraventricular nucleus. Brain Res. 945, 50-59 (2002).
97. Yehuda, R. Status of glucocorticoid alterations in post-traumatic stress disorder. Ann. NY Acad. Sci. 1179, 2056-2069 (2009).
98. Vecsernyes, M. , Biro, E. , Gardi, J. , Julesz, J. & Telegdy, G. Involvement of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral effects to ?-melanocyte-stimulating hormone. Endocr. Res. 26, 347-356 (2000).
99. Kas, M. J. , Bruijnzeel, A. W. , Haanstra, J. R. , Wiegant, V. M. & Adan, R. A. Differential regulation of agouti-related protein and neuropeptide Y in hypothalamic neurons following a stressful event. J. Mol. Endocrinol. 35, 159-164 (2005).
100. Serova, L. I. , Laukova, M. , Alaluf, L. G. & Sabban, E. L. Intranasal infusion of melanocortin receptor four (MC4R) antagonist to rats ameliorates development of depression and anxiety related symptoms induced by single prolonged stress. Behav. Brain Res. 250, 139-147 (2013). This is the first study to describe the resilience effects of HS014 on the development of behavioural symptoms comorbid with post-traumatic stress disorder.
101. Liu, J. et al. The melanocortinergic pathway is rapidly recruited by emotional stress and contributes to stress-induced anorexia and anxiety-like behavior. Endocrinology 148, 5531-5540 (2007).
102. Goyal, S. N. , Kokare, D. M. , Chopde, C. T. & Subhedar, N. K. Alpha-melanocyte stimulating hormone antagonizes antidepressant-like effect of neuropeptide Y in Porsolt's test in rats. Pharmacol. Biochem. Behav. 85, 369-377 (2006).
103. Vergoni, A. V. , Bertolini, A. , Wikberg, J. E. & Schioth, H. B. Selective melanocortin MC4R blockage reduces immobilization stress-induced anorexia in rats. Eur. J. Pharmacol. 369, 11-15 (1999).
104. Farooqi, I. S. et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. New Engl. J. Med. 348, 1085-1095 (2003).
105. Stutzmann, F. et al. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. Diabetes 57, 2511-2518 (2008).
106. Tan, K. et al. Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor. Endocrinology 150, 114-125 (2009).
107. Yeo, G. S. et al. Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum. Mol. Genet. 12, 561-574 (2003).
108. Agranat-Meged, A. et al. Attention deficit hyperactivity disorder in obese melanocortin-4-receptor (MC4R) deficient subjects: a newly described expression of MC4R deficiency. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 1547-1553 (2008).
109. Altfas, J. R. Prevalence of attention deficit/ hyperactivity disorder among adults in obesity treatment. BMC Psychiatry 2, 9 (2002).
110. Holtkamp, K. et al. Overweight and obesity in children with Attention-Deficit/Hyperactivity Disorder. Int. J. Obes. Relat. Metab. Disord. 28, 685-689 (2004).
111. Pagoto, S. L. et al. Association between adult attention deficit/hyperactivity disorder and obesity in the US population. Obesity 17, 539-544 (2009).
112. Waring, M. E. & Lapane, K. L. Overweight in children and adolescents in relation to attention-deficit/ hyperactivity disorder: results from a national sample. Pediatrics 122, e1-e6 (2008).
113. Pott, W. , Albayrak, O. , Hinney, A. , Hebebrand, J. & Pauli-Pott, U. Successful treatment with atomoxetine of an adolescent boy with attention deficit/ hyperactivity disorder, extreme obesity, and reduced melanocortin 4 receptor function. Obes. Facts 6, 109-115 (2013).
114. Cortese, S. et al. Association between symptoms of attention-deficit/ hyperactivity disorder and bulimic behaviors in a clinical sample of severely obese adolescents. Int. J. Obes. (Lond. ) 31, 340-346 (2007).
115. Albayrak, O. et al. Successful methylphenidate treatment of early onset extreme obesity in a child with a melanocortin-4 receptor gene mutation and attention deficit/hyperactivity disorder. Eur. J. Pharmacol. 660, 165-170 (2011).
116. Lindblom, J. et al. The MC4 receptor mediates ?-MSH induced release of nucleus accumbens dopamine. Neuroreport 12, 2155-2158 (2001).
117. Lindblom, J. et al. Chronic infusion of a melanocortin receptor agonist modulates dopamine receptor binding in the rat brain. Pharmacol. Res. 45, 119-124 (2002).
118. Von Frijtag, J. C. , Croiset, G. , Gispen, W. H. , Adan, R. A. & Wiegant, V. M. The role of central melanocortin receptors in the activation of the hypothalamus-pituitary-adrenal-axis and the induction of excessive grooming. Br. J. Pharmacol. 123, 1503-1508 (1998).
119. Welch, J. M. et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 448, 894-900 (2007).
120. Wan, Y. , Feng, G. & Calakos, N. Sapap3 deletion causes mGluR5-dependent silencing of AMPAR synapses. J. Neurosci. 31, 16685-16691 (2011).
121. Xu, P. et al. Double deletion of melanocortin 4 receptors and SAPAP3 corrects compulsive behavior and obesity in mice. Proc. Natl Acad. Sci. USA 110, 10759-10764 (2013). This is the first study to show that constitutive and induced genetic deletion of MC4R normalizes compulsive grooming in SAPAP3-null mice, offering insights into the treatment of compulsive behavioural and eating disorders.
122. Kokare, D. M. , Dandekar, M. P. , Singru, P. S. , Gupta, G. L. & Subhedar, N. K. Involvement of ?-MSH in the social isolation induced anxiety-and depression-like behaviors in rat. Neuropharmacology 58, 1009-1018 (2010).
123. Gonzalez, M. I. , Vaziri, S. & Wilson, C. A. Behavioral effects of ?-MSH and MCH after central administration in the female rat. Peptides 17, 171-177 (1996).
124. Rao, T. L. et al. GABAergic agents prevent alpha-melanocyte stimulating hormone induced anxiety and anorexia in rats. Pharmacol. Biochem. Behav. 76, 417-423 (2003).
125. Hirani, K. , Khisti, R. T. & Chopde, C. T. Behavioral action of ethanol in Porsolt's forced swim test: modulation by 3alpha-hydroxy-5alpha- pregnan-20-one. Neuropharmacology 43, 1339-1350 (2002).
126. Polidori, C. , Geary, N. & Massi, M. Effect of the melanocortin receptor stimulation or inhibition on ethanol intake in alcohol-preferring rats. Peptides 27, 144-149 (2006).
127. Kokare, D. M. , Singru, P. S. , Dandekar, M. P. , Chopde, C. T. & Subhedar, N. K. Involvement of alpha-melanocyte stimulating hormone (?-MSH) in differential ethanol exposure and withdrawal related depression in rat: neuroanatomical-behavioral correlates. Brain Res. 1216, 53-67 (2008).
128. Hadley, M. E. et al. Discovery and development of novel melanogenic drugs. Melanotan-I and-II. Pharm. Biotechnol. 11, 575-595 (1998).
129. Navarro, M. , Cubero, I. , Knapp, D. J. & Thiele, T. E. MTII-induced reduction of voluntary ethanol drinking is blocked by pretreatment with AgRP-(83-132). Neuropeptides 37, 338-344 (2003).
130. Lerma-Cabrera, J. M. et al. Adolescent binge-like ethanol exposure reduces basal ?-MSH expression in the hypothalamus and the amygdala of adult rats. Pharmacol. Biochem. Behav. 110, 66-74 (2013).
131. Szekely, J. I. et al. Attenuation of morphine tolerance and dependence by ?-melanocyte stimulating hormone (?-MSH). Life Sci. 24, 1931-1938 (1979).
132. Contreras, P. C. & Takemori, A. E. Antagonism of morphine-induced analgesia, tolerance and dependence by alpha-melanocyte-stimulating hormone. J. Pharmacol. Exp. Ther. 229, 21-26 (1984).
133. Jacquet, Y. F. Opiate effects after adrenocorticotropin or ?-endorphin injection in the periaqueductal gray matter of rats. Science 201, 1032-1034 (1978).
134. Starowicz, K. , Obara, I. , Przewlocki, R. & Przewlocka, B. Inhibition of morphine tolerance by spinal melanocortin receptor blockade. Pain 117, 401-411 (2005). This study suggests that antagonism of MC4R may be a possible new target in the search for strategies that prevent the development of opioid tolerance.
135. Niu, Z. et al. Melanocortin 4 receptor antagonists attenuates morphine antinociceptive tolerance, astroglial activation and cytokines expression in the spinal cord of rat. Neurosci. Lett. 529, 112-117 (2012).
136. Bronstein, D. M. , Przewlocki, R. & Akil, H. Effects of morphine treatment on pro-opiomelanocortin systems in rat brain. Brain Res. 519, 102-111 (1990).
137. Kalange, A. S. et al. Central administration of selective melanocortin 4 receptor antagonist HS014 prevents morphine tolerance and withdrawal hyperalgesia. Brain Res. 1181, 10-20 (2007).
138. Hervieu, G. J. et al. The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, slc-1, in the central nervous system of the rat. Eur. J. Neurosci. 12, 1194-1216 (2000).
139. Saito, Y. et al. Molecular characterization of the melanin-concentrating- hormone receptor. Nature 400, 265-269 (1999).
140. Bittencourt, J. C. et al. The melanin-concentrating hormone system of the rat brain: an immuno-and hybridization histochemical characterization. J. Comp. Neurol. 319, 218-245 (1992).
141. Chaki, S. , Okubo, T. & Sekiguchi, Y. Non-monoamine-based approach for the treatment of depression and anxiety disorders. Recent Pat. CNS Drug Discov. 1, 1-27 (2006).
142. Borowsky, B. et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nature Med. 8, 825-830 (2002).
143. Chaki, S. et al. Anxiolytic-and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. J. Pharmacol. Exp. Ther. 313, 831-839 (2005).
144. Walker, J. M. , Akil, H. & Watson, S. J. Evidence for homologous actions of pro-opiocortin products. Science 210, 1247-1249 (1980).
145. Sandman, C. A. & Kastin, A. J. Intraventricular administration of MSH induces hyperalgesia in rats. Peptides 2, 231-233 (1981).
146. Ohkubo, T. , Shibata, M. , Takahashi, H. & Naruse, S. Naloxone prevents the analgesic action of ?-MSH in mice. Experientia 41, 627-628 (1985).
147. Vrinten, D. H. , Kalkman, C. J. , Adan, R. A. & Gispen, W. H. Neuropathic pain: a possible role for the melanocortin system? Eur. J. Pharmacol. 429, 61-69 (2001).
148. Liu, H. et al. Transgenic mice expressing green fluorescent protein under the control of the melanocortin-4 receptor promoter. J. Neurosci. 23, 7143-7154 (2003).
149. Mountjoy, K. G. & Wild, J. M. Melanocortin-4 receptor mRNA expression in the developing autonomic and central nervous systems. Brain Res. Dev. Brain Res. 107, 309-314 (1998).
150. Starowicz, K. , Przewlocki, R. , Gispen, W. H. & Przewlocka, B. Modulation of melanocortin-induced changes in spinal nociception by ?-opioid receptor agonist and antagonist in neuropathic rats. Neuroreport 13, 2447-2452 (2002).
151. Beltramo, M. et al. Gene expression profiling of melanocortin system in neuropathic rats supports a role in nociception. Brain Res. Mol. Brain Res. 118, 111-118 (2003).
152. Mountjoy, K. G. The human melanocyte stimulating hormone receptor has evolved to become "super-sensitive" to melanocortin peptides. Mol. Cell. Endocrinol. 102, R7-R11 (1994).
153. Gautron, L. , Lee, C. E. , Lee, S. & Elmquist, J. K. Melanocortin-4 receptor expression in different classes of spinal and vagal primary afferent neurons in the mouse. J. Comp. Neurol. 520, 3933-3948 (2012).
154. Starowicz, K. , Bilecki, W. , Sieja, A. , Przewlocka, B. & Przewlocki, R. MC4R is expressed in the dorsal root ganglions and down-regulated in neuropathic rats. Neurosci. Lett. 358, 79-82 (2004).
155. Chu, H. , Sun, J. , Xu, H. , Niu, Z. & Xu, M. Effect of periaqueductal gray melanocortin 4 receptor in pain facilitation and glial activation in rat model of chronic constriction injury. Neurol. Res. 34, 871-888 (2012).
156. Vrinten, D. H. , Gispen, W. H. , Kalkman, C. J. & Adan, R. A. Interaction between the spinal melanocortin and opioid systems in a rat model of neuropathic pain. Anesthesiology 99, 449-454 (2003).
157. Starowicz, K. et al. Peripheral antinociceptive effects of MC4R antagonists in a rat model of neuropathic pain - a biochemical and behavioral study. Pharmacol. Rep. 61, 1086-1095 (2009).
158. Vrinten, D. H. , Gispen, W. H. , Groen, G. J. & Adan, R. A. Antagonism of the melanocortin system reduces cold and mechanical allodynia in mononeuropathic rats. J. Neurosci. 20, 8131-8137 (2000).
159. Chu, H. , Xia, J. , Yang, Z. & Gao, J. Melanocortin 4 receptor induces hyperalgesia and allodynia after chronic constriction injury by activation of p38 MAPK in DRG. Int. J. Neurosci. 122, 74-81 (2012). This study suggests a sequential role for MC4R that seems to depend on p38 MAPK activation in the induction and maintenance of neuropathic pain.
160. Bellasio, S. , Nicolussi, E. , Bertorelli, R. & Reggiani, A. Melanocortin receptor agonists and antagonists modulate nociceptive sensitivity in the mouse formalin test. Eur. J. Pharmacol. 482, 127-132 (2003).
161. Matthes, H. W. et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the ?-opioid-receptor gene. Nature 383, 819-823 (1996).
162. Arvidsson, U. et al. Distribution and targeting of a ?-opioid receptor (MOR1) in brain and spinal cord. J. Neurosci. 15, 3328-3341 (1995).
163. Kalyuzhny, A. E. , Arvidsson, U. , Wu, W. & Wessendorf, M. W. ?-Opioid and ?-opioid receptors are expressed in brainstem antinociceptive circuits: studies using immunocytochemistry and retrograde tract-tracing. J. Neurosci. 16, 6490-6503 (1996).
164. Alsio, J. et al. Enhanced sucrose and cocaine self-administration and cue-induced drug seeking after loss of VGLUT2 in midbrain dopamine neurons in mice. J. Neurosci. 31, 12593-12603 (2011).
165. McHugh, T. J. et al. Dentate gyrus NMDA receptors mediate rapid pattern separation in the hippocampal network. Science 317, 94-99 (2007).
166. Aponte, Y. , Atasoy, D. & Sternson, S. M. AGRP neurons are sufficient to orchestrate feeding behavior rapidly and without training. Nature Neurosci. 14, 351-355 (2011).
167. Xu, A. W. et al. PI3K integrates the action of insulin and leptin on hypothalamic neurons. J. Clin. Invest. 115, 951-958 (2005).
168. Begriche, K. , Girardet, C. , McDonald, P. & Butler, A. A. Melanocortin-3 receptors and metabolic homeostasis. Prog. Mol. Biol. Transl. Sci. 114, 109-146 (2013).
169. Zhang, F. et al. Optogenetic interrogation of neural circuits: technology for probing mammalian brain structures. Nature Protoc. 5, 439-456 (2010).
170. Sohn, J. W. et al. Melanocortin 4 receptors reciprocally regulate sympathetic and parasympathetic preganglionic neurons. Cell 152, 612-619 (2013).
171. Lee, Y. S. et al. Design and synthesis of trivalent ligands targeting opioid, cholecystokinin, and melanocortin receptors for the treatment of pain. Bioorg. Med. Chem. Lett. 20, 4080-4084 (2010).
172. Leone, S. , Noera, G. & Bertolini, A. Melanocortins as innovative drugs for ischemic diseases and neurodegenerative disorders: established data and perspectives. Curr. Med. Chem. 20, 735-750 (2013).
173. Spaccapelo, L. et al. Up-regulation of the canonical Wnt-3A and Sonic hedgehog signaling underlies melanocortin-induced neurogenesis after cerebral ischemia. Eur. J. Pharmacol. 707, 78-86 (2013).
174. Arnason, B. G. , Berkovich, R. , Catania, A. , Lisak, R. P. & Zaidi, M. Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult. Scler. 19, 130-136 (2013).
175. Kuo, J. J. , da Silva, A. A. , Tallam, L. S. & Hall, J. E. Role of adrenergic activity in pressor responses to chronic melanocortin receptor activation. Hypertension 43, 370-375 (2004).
176. Kievit, P. et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 62, 490-497 (2013). This study demonstrates, for the first time, that highly selective melanocortin peptide drugs can be used for the treatment of weight loss.
177. Rask-Andersen, M. , Masuram, S. & Schioth, H. B. The druggable genome: evaluation of drug targetsin clinical trials suggests major shifts in molecular class and indication. Annu. Rev. Pharmacol. Toxicol. 54, 9-26 (2014).
178. Grove, K. L. & Smith, M. S. Ontogeny of the hypothalamic neuropeptide Y system. Physiol. Behav. 79, 47-63 (2003).
179. Sebag, J. A. , Zhang, C. , Hinkle, P. M. , Bradshaw, A. M. & Cone, R. D. Developmental control of the melanocortin-4 receptor by MRAP2 proteins in zebrafish. Science 341, 278-281 (2013).
180. Morris, M. J. Early life influences on obesity risk: maternal overnutrition and programming of obesity. Expert Rev. Endocrinol. Metab. 4, 625-637 (2009). This review provides a clear and comprehensive picture of the involvement of the intra-uterine environment in neurocircuit development.
181. Mcmillen, I. C. & Robinson, J. S. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol. Rev. 85, 571-633 (2005).
182. Poston, L. Developmental programming and diabetes - the human experience and insight from animal models. Best Pract. Res. Clin. Endocrinol. Metab. 24, 541-552 (2010).
183. Gluckman, P. D. , Hanson, M. A. , Spencer, H. G. & Bateson, P. Environmental influences during development and their later consequences for health and disease: implications for the interpretation of empirical studies. Proc. R. Soc. B 272, 671-677 (2005).
184. Lucas, A. Programming by early nutrition in man. Ciba Found Symp. 156, 38-50 (1991).
185. Barker, D. J. P. , Bull, A. R. , Osmond, C. & Simmonds, S. J. Fetal and placental size and risk of hypertension in adult life. Int. J. Gynecol. Obstetr. 35, 97-98 (1991).
186. Grove, K. L. , Grayson, B. E. , Glavas, M. M. , Xiao, X. Q. & Smith, M. S. Development of metabolic systems. Physiol. Behav. 86, 646-660 (2005).
187. Gluckman, P. D. & Hanson, M. A. Developmental and epigenetic pathways to obesity: an evolutionary-developmental perspective. Int. J. Obes. 32 (Suppl. 7), 62-71 (2005).
188. Dobbing, J. & Sands, J. Comparative aspects of the brain growth spurt. Early Hum. Dev. 3, 79-83 (1979).
189. Grayson, B. E. et al. Prenatal development of hypothalamic neuropeptide systems in the nonhuman primate. Neuroscience 143, 975-986 (2006).
190. Catania, A. et al. The neuropeptide ?-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Peptides 17, 675-679 (1996).
191. Bhardwaj, R. et al. Evidence for the differential expression of the functional ?-melanocyte-stimulating hormone receptor MC-1 on human monocytes. J. Immunol. 158, 3378-3384 (1997).
192. Xia, Y. , Wikberg, J. E. & Chhajlani, V. Expression of melanocortin 1 receptor in periaqueductal gray matter. Neuroreport 6, 2193-2196 (1995).
193. Catania, A. , Gatti, S. , Colombo, G. & Lipton, J. M. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol. Rev. 56, 1-29 (2004).
194. Isales, C. M. , Zaidi, M. & Blair, H. C. ACTH is a novel regulator of bone mass. Ann. NY Acad. Sci. 1192, 110-116 (2010).
195. Zaidi, M. et al. ACTH protects against glucocorticoid-induced osteonecrosis of bone. Proc. Natl Acad. Sci. USA 107, 8782-8787 (2010).
196. Pan, X. C. , Song, Y. T. , Liu, C. , Xiang, H. B. & Lu, C. J. Melanocortin-4 receptor expression in the rostral ventromedial medulla involved in modulation of nociception in transgenic mice. J. Huazhong Univ. Sci. Technolog. Med. Sci. 33, 195-198 (2013).
197. Kistler-Heer, V. , Lauber, M. E. & Lichtensteiger, W. Different developmental patterns of melanocortin MC3 and MC4 receptor mRNA: predominance of Mc4 in fetal rat nervous system. J. Neuroendocrinol. 10, 133-146 (1998).
198. Padilla, S. L. , Reef, D. & Zeltser, L. M. Defining POMC neurons using transgenic reagents: impact of transient Pomc expression in diverse immature neuronal populations. Endocrinology 153, 1219-1231 (2012).
199. Van der Kraan, M. et al. Expression of melanocortin receptors and pro-opiomelanocortin in the rat spinal cord in relation to neurotrophic effects of melanocortins. Mol. Brain Res. 63, 276-286 (1999).
200. Overstreet, L. S. et al. A transgenic marker for newly born granule cells in dentate gyrus. J. Neurosci. 24, 3251-3259 (2004).
201. Okamoto, K. , Nagai, T. , Miyawaki, A. & Hayashi, Y. Rapid and persistent modulation of actin dynamics regulates postsynaptic reorganization underlying bidirectional plasticity. Nature Neurosci. 7, 1104-1112 (2004).
202. Zuo, Y. , Lin, A. , Chang, P. & Gan, W. B. Development of long-term dendritic spine stability in diverse regions of cerebral cortex. Neuron 46, 181-189 (2005).
203. Boudreau, A. C. , Reimers, J. M. , Milovanovic, M. & Wolf, M. E. Cell surface AMPA receptors in the rat nucleus accumbens increase during cocaine withdrawal but internalize after cocaine challenge in association with altered activation of mitogen-activated protein kinases. J. Neurosci. 27, 10621-10635 (2007).
204. Waltereit, R. & Weller, M. Signaling from cAMP/PKA to MAPK and synaptic plasticity. Mol. Neurobiol. 27, 99-106 (2003).
205. Kang, H. et al. An important role of neural activity-dependent CaMKIV signaling in the consolidation of long-term memory. Cell 106, 771-783 (2001).
206. Zhou, Q. , Homma, K. J. & Poo, M. M. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron 44, 749-757 (2004).
207. Gloerich, M. & Bos, J. L. Epac: defining a new mechanism for cAMP action. Annu. Rev. Pharmacol. Toxicol. 50, 355-375 (2010).
208. Schiöth, H. B. et al. Evolutionary conservation of the structural, pharmacological, and genomic characteristics of the melanocortin receptor subtypes. Peptides 26, 1886-1900 (2005).
209. Mountjoy, K. G. , Robbins, L. S. , Mortrud, M. T. & Cone, R. D. The cloning of a family of genes that encode melanocortin receptors. Science 257, 1248-1251 (1992).
210. Valsalan, R. , Krishnan, A. , Almén, M. S. , Fredriksson, R. & Schiöth, H. B. Early vertebrate origin of melanocortin 2 receptor accessory proteins (MRAPs). Gen. Comp. Endocrinol. 188, 123-132 (2013).
211. Klovins, J. et al. The melanocortin system in Fugu: determination of POMC/AGRP/MCR gene repertoire and synteny, as well as pharmacology and anatomical distribution of the MCRs. Mol. Biol. Evol. 21, 563-579 (2004).
212. Schiöth, H. B. et al. Functional role, structure, and evolution of the melanocortin-4 receptor. Ann. NY Acad. Sci. 994, 74-83 (2003).
213. Kay, E. I. , Botha, R. , Montgomery, J. M. & Mountjoy, K. G. hMRAPa increases ?MSH-induced hMC1R and hMC3R functional coupling and hMC4R constitutive activity. J. Mol. Endocrinol. 50, 203-215 (2013).
214. Kay, E. I. , Botha, R. , Montgomery, J. M. & Mountjoy, K. G. hMRAPa specifically alters hMC4R molecular mass and N-linked complex glycosylation in HEK293 cells. J. Mol. Endocrinol. 50, 217-227 (2013).
215. Mountjoy, K. G. , Jenny Wu, C. S. , Dumont, L. M. & Wild, J. M. Melanocortin-4 receptor messenger ribonucleic acid expression in rat cardiorespiratory, musculoskeletal, and integumentary systems. Endocrinology 144, 5488-5496 (2003).
216. Mountjoy, K. G. , Wu, C. S. , Cornish, J. & Callon, K. E. ?-MSH and desacetyl-?-MSH signaling through melanocortin receptors. Ann. NY Acad. Sci. 994, 58-65 (2003).
217. Tanabe, K. , Gamo, K. , Aoki, S. , Wada, K. & Kiyama, H. MC4R is induced in nerve-injured motor and sensory neurons of mouse. J. Neurochem. 101, 1145-1152 (2007).
218. Sawyer, T. K. et al. 4-Norleucine, 7-D-phenylalanine-?-melanocyte- stimulating hormone: a highly potent ?-melanotropin with ultralong biological activity. Proc. Natl Acad. Sci. USA 77, 5754-5758 (1980).
219. Dorr, R. T. et al. Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 58, 1777-1784 (1996).
220. Abou-Mohamed, G. et al. HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J. Pharmacol. Exp. Ther. 275, 584-591 (1995).
221. Wikberg, J. E. S. Melanocortin receptors: perspectives for novel drugs. Eur. J. Pharmacol. 375, 295-310 (1999).
222. Hruby, V. J. et al. Cyclic lactam ?-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] ?-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J. Med. Chem. 38, 3454-3461 (1995).
223. Schioth, H. B. et al. Further pharmacological characterization of the selective melanocortin 4 receptor antagonist HS014: comparison with SHU9119. Neuropeptides 33, 191-196 (1999).